University of Wollongong

Research Online
Faculty of Science, Medicine and Health Papers: part A

Faculty of Science, Medicine and Health

1-1-2012

Supporting Treatment decision making to Optimise the Prevention of
STROKE in Atrial Fibrillation: The STOP STROKE in AF study. Protocol for a
cluster randomised controlled trial
Melina Gattellari
Ingham Institute, University of New South Wales

John M. Worthington
Ingham Institute, University of New South Wales, South Western Sydney Local Health District

Dominic Y. Leung
South Western Sydney Local Health District, University of New South Wales

Nicholas Arnold Zwar
University of New South Wales, nzwar@uow.edu.au

Follow this and additional works at: https://ro.uow.edu.au/smhpapers
Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences
Commons

Recommended Citation
Gattellari, Melina; Worthington, John M.; Leung, Dominic Y.; and Zwar, Nicholas Arnold, "Supporting
Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: The STOP STROKE
in AF study. Protocol for a cluster randomised controlled trial" (2012). Faculty of Science, Medicine and
Health - Papers: part A. 4434.
https://ro.uow.edu.au/smhpapers/4434

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Supporting Treatment decision making to Optimise the Prevention of STROKE in
Atrial Fibrillation: The STOP STROKE in AF study. Protocol for a cluster
randomised controlled trial
Abstract
Background: Suboptimal uptake of anticoagulation for stroke prevention in atrial fibrillation has persisted
for over 20 years, despite high-level evidence demonstrating its effectiveness in reducing the risk of fatal
and disabling stroke.Methods: The STOP STROKE in AF study is a national, cluster randomised controlled
trial designed to improve the uptake of anticoagulation in primary care. General practitioners from around
Australia enrolling in this 'distance education' program are mailed written educational materials, followed
by an academic detailing session delivered via telephone by a medical peer, during which participants
discuss patient de-identified cases. General practitioners are then randomised to receive written
specialist feedback about the patient de-identified cases either before or after completing a three-month
posttest audit. Specialist feedback is designed to provide participants with support and confidence to
prescribe anticoagulation. The primary outcome is the proportion of patients with atrial fibrillation
receiving oral anticoagulation at the time of the posttest audit.Discussion: The STOP STROKE in AF study
aims to evaluate a feasible intervention via distance education to prevent avoidable stroke due to atrial
fibrillation. It provides a systematic test of augmenting academic detailing with expert feedback about
patient management.Trial registration: Australian Clinical Trials Registry Registration Number:
ACTRN12611000076976. 2012 Gattellari et al.; licensee BioMed Central Ltd.
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Supporting Treatment decision making to
Optimise the Prevention of STROKE in Atrial
Fibrillation: The STOP STROKE in AF study.
Protocol for a cluster randomised controlled trial
Melina Gattellari1,2, John M Worthington1,3,4*, Dominic Y Leung3,5 and Nicholas Zwar2

Abstract
Background: Suboptimal uptake of anticoagulation for stroke prevention in atrial fibrillation has persisted for
over 20 years, despite high-level evidence demonstrating its effectiveness in reducing the risk of fatal and disabling
stroke.
Methods: The STOP STROKE in AF study is a national, cluster randomised controlled trial designed to improve the
uptake of anticoagulation in primary care. General practitioners from around Australia enrolling in this ‘distance
education’ program are mailed written educational materials, followed by an academic detailing session delivered
via telephone by a medical peer, during which participants discuss patient de-identified cases. General practitioners
are then randomised to receive written specialist feedback about the patient de-identified cases either before or
after completing a three-month posttest audit. Specialist feedback is designed to provide participants with support
and confidence to prescribe anticoagulation. The primary outcome is the proportion of patients with atrial
fibrillation receiving oral anticoagulation at the time of the posttest audit.
Discussion: The STOP STROKE in AF study aims to evaluate a feasible intervention via distance education to
prevent avoidable stroke due to atrial fibrillation. It provides a systematic test of augmenting academic detailing
with expert feedback about patient management.
Trial registration: Australian Clinical Trials Registry Registration Number: ACTRN12611000076976.
Keywords: Atrial fibrillation, General practice, Anticoagulation, Decisional support

Background
Atrial fibrillation (AF) is the most common heart
arrhythmia with a prevalence of around 5% in those aged
over 65, increasing to 10% in those older than 75 years
[1]. AF confers the highest risk for ischaemic stroke of
all traditional risk factors, including congestive heart failure, diabetes, and hypertension [2]. In Australia, at least
one in four patients admitted to hospital with an ischaemic stroke has AF [3]. Mortality in stroke patients with
AF is around twice the rate in those without it; by
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12 months, 40% of ischaemic stroke patients with AF
will have died [3]. Moreover, survivors of AF-related
stroke spend a significantly longer time in hospital [3].
Meta-analyses of randomised controlled trials of
antithrombotic medication demonstrate that, in the
average AF patient with a 5% chance of an ischaemic
stroke each year, oral anticoagulation with adjusted-dose
warfarin reduces this annual risk by 67%, in relative
terms, to approximately 1.7% [4]. In contrast, antiplatelet
medication, such as aspirin, reduces the risk by only
21%, to approximately 4% [4]. Despite over 20 years of
evidence supporting lifelong anticoagulation as the treatment of choice for most patients with AF [4-6], 50%–
60% of patients do not receive anticoagulants even if
they are at high risk of stroke [7,8]. An Australian study

© 2012 Gattellari et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Gattellari et al. Implementation Science 2012, 7:63
http://www.implementationscience.com/content/7/1/63

of 218 consecutively admitted patients with AF reported
that only 20% were using warfarin on admission [9], although inclusion of an unspecified number of newly
diagnosed AF cases would have influenced the reported
proportion of under use [9]. In a Canadian stroke unit,
90% of admitted ischaemic stroke patients with AF were
not receiving anticoagulation or were insufficiently
anticoagulated at the time of their stroke [10]. In one
Australian stroke unit, 68% of ischaemic stroke patients
with known AF before admission either were not anticoagulated or were sub-optimally anticoagulated at the
time of their stroke [11]. This persistent evidence–practice gap contributes to the burden of preventable stroke.
Clinicians are often reluctant to prescribe anticoagulation for AF, particularly if patients are elderly or have a
heightened risk of falls or other perceived risk of major
bleeding [12-19]. However, many patients considered
unsuitable for anticoagulation also have an elevated risk
of ischaemic stroke, and the risk-benefit trade-off
favours anticoagulation in the majority of patients with
AF [20-24].
Few studies have evaluated implementation strategies
specifically designed to increase the uptake of oral anticoagulation for AF. McAlister et al. [25] reported an increase
in antithrombotic prescribing at three months in general
practice patients receiving a decision aid. The difference
was not sustained at 12 months after randomisation. In a
nonrandomised study of Australian primary healthcare
physicians in one geographical region of Tasmania, guideline dissemination followed by academic-detailing visits
significantly increased prescribing rates of adjusted-dose
warfarin compared to a control region [26]. Two other
studies in the primary healthcare setting addressed several
cardiovascular risk factors, without focusing specifically
on AF management [27,28]. Ornstein et al. [27] tested the
effect of computerised guidelines, reminder systems, and
audit and feedback on prescribing behaviour in managing
several cardiovascular risk factors. Posttest differences between intervention and control groups were not statistically significant. Another trial found that locally adapted
guidelines, an educational seminar delivered by local opinion leaders, educational materials, and an offer of an educational outreach visit did not increase primary healthcare
physicians’ adherence to prescribing guidelines for patients
with a history of transient ischaemic attack (TIA) or AF
[28]. The outcome measure in this study did not distinguish between anticoagulant and antiplatelet prescribing.
Other randomised evaluations of implementation
strategies have been carried out with stroke survivors to
optimise secondary prevention [29-33]. These have
included few AF patients (n = 6 to n = 99) [29-33], and of
the two studies reporting outcomes for AF patients, neither found statistically significant improvements in anticoagulant prescribing [32,33].
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Specialist decisional support for general practitioners
(GPs) merits further investigation. A recent evaluation
of a shared-care model for stroke survivors involved liaison between GPs and stroke specialists, facilitated via a
nurse specialist. The study found significant improvements in the management of secondary stroke risk and,
for AF patients, a nonsignificant improvement in anticoagulation prescribing attributable to the intervention
[32]. However, the total number of AF patients in this
study was small (n = 32). While the multifaceted nature
of the study intervention precludes the identification of
effective components, it suggests that linking GPs with
stroke specialists could enhance clinical decision making. An observational study also reported a significant
effect of collaborative involvement between specialists
and GPs on appropriate anticoagulation prescribing,
providing further support for the hypothesis that specialist input may be effective in improving the management
of AF patients [34].
In another study, known as DESPATCH, we are evaluating the effect of expert decisional support to promote
the uptake of anticoagulation using feedback from clinical experts in stroke medicine [35]. However, in the
DESPATCH study, decisional support is embedded
within a multifaceted intervention including written educational materials, three telephone academic-detailing
sessions, and a workshop/seminar. We have designed the
STOP STROKE in AF study to systematically assess the
impact of expert decisional support on the management
of AF in a national study.

Methods
Please see attached file (Additional file 1) for the study
flow diagram.
GP recruitment

We obtained contact details of GPs from a commercially
available database [36], which sources information from
professional colleges, medical directories, and state medical boards that register all practising clinicians in Australia. After an initial pilot with 100 randomly selected GPs to
determine the likely participation rate, we undertook
recruitment in two phases, obtaining lists of 3,000 randomly selected GPs from across Australia in 2010 and
2,501 in 2011 (with those selected in 2010 removed from
the sampling frame). GPs who were participating in another implementation trial about AF we were carrying out
[37] were excluded from the randomly selected samples
(n = 10 in 2010 and n = 13 in 2011).
GPs were mailed a brief introductory letter inviting
them to complete a registration form, to be returned by
fax or an enclosed business reply paid envelope, advising
us of their interest in an education program about stroke
prevention. During the first (i.e., in 2010) and second
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phases of recruitment (i.e., in 2011), we carried out two
randomised trials of response-aiding strategies, both of
which received ethics approval as amendments to the
main study protocol. During the first phase, a statistician
independent of the research team randomised 2,250 GPs
into three equal-sized groups (n = 750 for each group).
The first group was mailed the introductory letter and
registration form in an institutional 110 mm by
220 mm-sized envelope (DL-sized) with the university
logo and address printed in black and white on the top
left-hand corner. The second group was mailed the letter
and form in the institutional envelope and also received
complimentary copies of resources provided free of
charge by the National Stroke Foundation (NSF) of
Australia. The third group was also mailed the NSF
resources with their letter and form but received these
via an Australia Post “Express Post” envelope representing “priority mail”. The remaining 740 GPs were not
included in this trial and were mailed the introductory
letter and registration form at a different time point to
those selected to test response-aiding strategies. During
the second wave of recruitment, 2,488 GPs were randomly divided to receive the cover letter and registration
form printed on pale yellow (n = 1,247) or white paper
(n = 1,240). Letters were mailed using the institutional
DL-sized envelopes with logo and address printed in
black and white. This trial was separately registered
(ACTRN12611000259943).
GPs who returned their registration forms were mailed
an information sheet and a consent form, advising that
consenting GPs would be invited to participate in an
educational session delivered by a medically trained peer
via telephone, after which they would be randomised to
receive specialist feedback about the de-identified patient
cases (see description of intervention below). GPs who
returned a signed consent form by fax or enclosed reply
paid envelope were then mailed educational materials in
advance of a telephone educational session to be delivered by medical peers. Only those GPs who complete the
telephone educational session, providing pretest data, are
considered recruited and eligible for randomisation. During the initial stages of the first recruitment phase (i.e., in
2010), GPs returning their registration form were telephoned in advance of receiving the information sheet
and consent form, and those GPs not returning a consent
form within a minimum of two weeks were mailed a second copy. However, due to resource constraints, this
follow-up protocol was abandoned.
Academic detailing

Enrolled GPs receive printed education materials (see
Additional file 2) prior to being contacted by a medically
trained peer who carried out a standardised telephone
educational session covering key issues concerning the
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management of AF (see Additional file 3). Topics include
the epidemiology of AF [1-3], risk stratification using the
validated tools [37], and information about the benefits
and risks of antithrombotic medications used to manage
AF, including adjusted-dose warfarin and antiplatelet
medication, such as aspirin and/or clopidogrel [38-44].
During 2011, the information was revised to include information about a revised risk stratification scheme [45]
and dabigatran [46-48], a newly available fixed-dose anticoagulant that received regulatory approval in Australia
for stroke prophylaxis in AF in May 2011.
GPs were advised in advance of the telephone educational session to identify patients with AF who are over
the age of 65 and not receiving anticoagulation or for
whom anticoagulation management had presented difficulties. GPs enrolled during the first phase of recruitment (i.e., in 2010) were advised to select around three
or four patients for discussion with the medical peer,
while those recruited during the second phase (i.e.,
from 2011 onwards) were advised to select a minimum
of five patients.
At the conclusion of the telephone educational session,
the medically trained peer proceeded through a standardised patient pro forma, collecting de-identified information about patient demographics, stroke risk factors,
other comorbidities, current antithrombotic medications, and issues relevant to anticoagulation use. Medically trained peers calculated the patient’s CHADS2 score
with participating GPs, providing general feedback based
on evidence-based guideline recommendations, according to patients’ CHADS2 scores [24]. The CHADS2 score
assigns two points for prior stroke or TIA and one point
each for the following risk factors: congestive heart failure, history of hypertension, age over 75, and diabetes.
Key safety messages about stroke risk in paroxysmal AF,
hypertension, and use of antithrombotic treatment in
patients with a history of spontaneous intracranial
haemorrhage were also communicated. From late 2011,
medical peers also communicated a safety alert issued by
the peak Australian drug regulatory body, the Therapeutics Goods Administration (TGA), about the risks of
using dabigatran, a newly available oral anticoagulant, in
the elderly and in patients with renal impairment [49].
Pretest data collection

Before commencing the academic-detailing session,
medical peers noted GPs’ gender and asked participants
to report the number of doctors in their practice and
whether they were practising full-time or part-time.
Medical peers asked GPs whether they had any of the
following resources available to assist them in managing
AF patients receiving warfarin: a nurse to monitor and
recall patients when needed; automated or computerised
reminders for noting when patients need to have their
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International Normalised Ratios INR levels tested;
point-of-care INR testing; pathology service anticoagulation management; or hospital clinical anticoagulation
management, practice-based register, or utilisation of a
formal Australian government program whereby pharmacists visit patients to monitor compliance with medications. A modified version of the Provider Decision
Process Assessment Instrument [50] measuring GP
levels of decisional conflict regarding warfarin use was
administered. GPs were asked to indicate their level of
agreement (agree, disagree, neither) to five statements
(‘Whether or not to prescribe warfarin is a difficult
decision to make’, ‘For most patients it is clear that warfarin is the best treatment’, ‘It is often difficult to decide if
the benefits of warfarin outweigh the risks, or vice versa’,
‘Generally, patients fully appreciate the benefits of warfarin’, ‘Generally, patients fully appreciate the risks of
warfarin’). Finally, medical peers asked GPs whether
they had participated in formal educational activities
about AF in the previous 12 months.
The de-identified patient pro forma document contributed to the pretest patient-level data for this study.
Information on patient age and sex was first elicited.
GPs were then asked to clarify whether the patient
had paroxysmal or chronic AF (a response of unsure
was permitted) and whether the patient had underlying
valvular heart disease or nonvalvular AF. Medical peers
asked GPs to indicate if the patient had thyrotoxicosis
(yes/no/unsure). Relevant medical history ascertaining
stroke risk factors to enable calculation of the
CHADS2 score was elicited. History of myocardial infarction, peripheral artery disease, aortic plaque, coronary artery disease, and high cholesterol/hyperlipidemia
was also noted, as was current smoking status.
Relevant comorbidities reflecting actual or perceived
contraindications to anticoagulation were also elicited.
These included the following: falls history (without and
without injury), a history of multiple falls, anaemia, recent or current upper gastrointestinal (GI) bleeding
within the last month, history of upper GI bleeding, history of lower GI bleeding, history of GI bleeding (location not specified), a treated cause of GI bleeding,
cerebral haemorrhage, hepatic insufficiency/moderate to
severe liver disease, impaired kidney function, chronic
dialysis, renal implantation, abnormal serum creatinine
(>200 ųmol/L), hepatic derangement on biochemical
testing, excessive alcohol intake (defined as eight or
more units per week), coagulopathy, thrombocytopaenia,
dementia or cognitive impairment (with and without
supervised care), insertion of coronary artery stent
(drug-eluting, bare metal, or stent of unknown type),
and nonadherence with medication or management.
Comorbidities assessing bleeding risk as described above
were derived from a standardised scheme [51]. GP
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participants could nominate other comorbidities they
considered relevant for specialist feedback. The pro
forma elicited information on current antithrombotic
medications; previous use of anticoagulation with
adjusted-dose warfarin; and, where relevant, reasons for
not using warfarin, for ceasing warfarin, and adverse
events whilst receiving warfarin (minor bleeding not requiring hospitalisation, major blood loss requiring hospitalisation, intracranial or intracerebral haemorrhage,
including subarachnoid haemorrhage; ischaemic stroke;
TIA or amaurosis fugax; sub-therapeutic INR levels;
supra-therapeutic INR levels; consistently unstable INR
levels). Rate- or rhythm-control medications, nonsteroidal anti-inflammatory drugs (NSAIDs) including
COX-2 inhibitors, paracetamol, alternative medications,
and other over-the-counter medications in current use
were also noted. From 2011 onwards, GPs were asked to
note, where relevant, adverse events whilst receiving anticoagulants other than warfarin (most likely dabigatran).
Randomisation

A statistician external to the study group is carrying out
randomisation after participants complete academicdetailing sessions. Randomisation is being stratified by
the number of cases GPs identify (≤2 or >3). Results of
randomisation are communicated to the study coordinator (MG) who assigns GPs to their respective groups.
The statistician involved in the analysis of the trial will
receive the randomisation schedule directly from the statistician carrying out randomisation. Block randomisation is being used to control for date of entry into the
trial. Block size will be disclosed to the study team only
during the write-up of results.
Expert decisional support

Medically trained peers reminded GPs that they will be
randomised to receive specialist feedback about patient
de-identified cases either prior to or after posttest evaluation. They were advised to consider this component of
the intervention as an educational exercise and, therefore, should not have expectations of timely feedback
and should seek any urgently required advice through
their usual practices. Data from the de-identified pro
forma documents were mailed to MG, who entered the
data and summarised information into a one- to twopage document that was forwarded to experts in either
neurology, cardiology and stroke. The experts provided
written information that was then mailed to GPs randomised to receive expert decisional support prior to the
posttest phase of the study (see Additional file 4 for a
hypothetical example). Our model for delivering this aspect of the intervention was informed by an intervention
developed by McAlister et al., 2006 [52].
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Waiting list control

GPs randomised to the waiting list control group were
mailed a summary of patient de-identified information,
identical to the summary received by GPs randomised to
the intervention arm. These GPs also received a statement summarising patient ischaemic stroke risk based
on the patient’s CHADS2 score. Therefore, patient summaries were identical between groups, with the exception of specialist written feedback.
Posttest data collection

Posttest data collection is scheduled for approximately
12 weeks after GPs have received either the expert decisional feedback or, for those randomised to the waiting list
control group, the patient de-identified summary document. GPs receive another copy of the patient de-identified
summary sheet (without expert feedback) attached to a
brief posttest questionnaire. For each patient, GPs are asked
to indicate current antithrombotic treatment from a list of
available choices (warfarin, aspirin, clopidogrel, aspirin and
clopidogrel, dipyridamole, dipyridamole with aspirin, dabigatran, other antithrombotic for GP to specify, or no
antithrombotic) and, if currently receiving warfarin, to report the last six INR test results and corresponding dates of
blood collection. In response to a checklist of items, GPs
are asked to specify reasons for any given patient not receiving anticoagulation (patient refusal/reluctance, history
of traumatic brain haemorrhage, history of spontaneous
brain haemorrhage, history of lower GI bleed, history of
upper GI bleed, falls history without injury, falls history
with injury, history of GI location not specified, age, cognitive impairment, inadequate supervision at home, patient
nonadherence with medication, patient nonadherence with
monitoring, specialist doesn’t recommend anticoagulation,
patient at low risk of stroke, awaiting government subsidisation of fixed-dose anticoagulation with dabigatran, or
other reason which GPs are asked to specify).
Whether or not patients are receiving anticoagulation,
GPs complete an adapted version of the Provider Decision Process Assessment Instrument [50], consisting of
six items assessing GP levels of decisional conflict
regarding anticoagulation with adjusted-dose warfarin,
with an additional question asking GPs to indicate their
level of satisfaction with the current treatment. From
2011 onwards, the posttest evaluation included an additional six questions assessing levels of decisional conflict
for a newly available fixed-dose anticoagulant, dabigatran. Posttest data will be entered by personnel blinded
to group allocation.
Primary outcome

The primary outcome is defined as the proportion of
patients with AF who, at posttest, are reported by GPs
to be receiving anticoagulation.
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Secondary endpoints
Appropriate antithrombotic treatment according to
stroke risk

In accordance with evidence-based guidelines [38-40],
we will use baseline CHADS2 scores in those patients
aged over 65 years to judge appropriateness of antithrombotic management. Specifically, patients over 65 years
of age with a baseline CHADS2 score of 0 will be considered to be managed appropriately if receiving aspirin,
while those with a baseline CHADS2 score of 2 or more
will be considered to be receiving appropriate antithrombotic treatment if receiving anticoagulation (either with
warfarin or dabigatran). Either anticoagulation or aspirin
will be considered appropriate in those with a baseline
CHADS2 score of 1. The expected few cases of patients
younger than 65 years of age will be excluded from
this analysis. However, a sensitivity analysis will be
carried out applying the CHADS2 score to patients
younger than 65 years of age, as above, in recognition of
inclusion criteria used in recent trials of antithrombotic
treatments that included patients younger than 65
where AF was associated with CHADS2 stroke risk factors [4-6].
Appropriate antithrombotic treatment according to stroke
risk incorporating quality-control criteria

In those patients receiving anticoagulation with warfarin,
we will only consider anticoagulation to be appropriate
for this outcome if GPs, when reporting the six most recent INR results, report an INR result at least monthly
and where at least four of the six test results (or twothirds of results in cases where fewer than six are
reported) are within therapeutic range (i.e., within 2.0–
3.0). These criteria for appropriate anticoagulation are
based on local guidelines [44] and a consistently achieved
standard of ‘time in therapeutic range’ reported in clinical trials [4-6], including one trial of general practice
patients with an average age of 81 years [6].
Further refinement of outcome definition

Combinations of antiplatelet therapies with or without
anticoagulation may diverge from standard guideline
recommendations but may nonetheless be appropriate
in the context of aspirin intolerance, patients with a history of coronary stenting, or in those affected by acute
coronary syndromes [42,43,53-55]. We will accept other
antiplatelet treatments, such as clopidogrel, dypridamole,
and combinations of these treatments, where aspirin
would have been considered the evidence-based treatment. Where anticoagulation is considered the evidencebased choice, we will not distinguish between cases
where anticoagulation is used alone or in combination
with other antithrombotics.
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Decisional conflict

Scores comprising the seven-item decisional conflict
scale, based on a previously validated measure [50]
adapted for use in our earlier work and in other studies
[13,14], will be summed to produce a total score,
whereby higher scores indicate higher levels of decisional conflict (range = 7 to 35). At the time of writing, warfarin remains the only anticoagulant treatment that is
available to all Australian residents via Australia’s universal health insurance scheme ensuring government subsidisation of medication. The fixed-dose anticoagulant
dabigatran has received regulatory approval for AF but
is not currently subsidised by the Australian government. Consequently, the uptake of dabigatran is not
expected to be high, and we will restrict this outcome to
items assessing decisional conflict about warfarin only,
unless uptake of dabigatran is found to be common.
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cluster size and ρ equals the intraclass correlation coefficient. We have selected a value of m to produce anticonservative (i.e., larger) estimates of the required GP
sample, as the number of GPs needed will have a greater
effect on study resources and its feasibility than the
numbers of patient cases identified by GPs. Smaller
values of m will produce a sample size estimate requiring greater numbers of GPs. Assuming an average cluster size of three and selecting an intraclass correlation
coefficient of 0.029, informed by results from a previous
study [27], our anticipated design effect was 1.06 (i.e.,
1 + (3 – 1) × 0.029), producing a required total sample
size of 1.06 × 340 = 361. Assuming 20% of posttest audit
questionnaires are not returned by GPs, we require data
on 452 de-identified patient cases or 226 per group. If
GPs each select three patient cases on average, then we
will need to recruit 76 GPs per group (i.e., 226/3), or
152 in total.

Sensitivity analyses

In cases that are lost to follow-up (for example, where
GPs do not return their posttest audit questionnaires),
we will reanalyse our primary and secondary outcomes
relating to prescribing behaviour, firstly, assuming no
change in antithrombotic management from baseline to
posttest and secondly, assuming the desired outcome
was not achieved.

Statistical analysis

Outcomes will be analysed according to the intentionto-treat principle, whereby patients are analysed according to the arm to which their GP cluster was allocated.
Clustering will be accounted for at the practice level
[57]. A p value of < .05 will be used to determine statistical significance of results. Analyses will be carried out
by a statistician blinded to group allocation.

Subgroup analyses

We will carry out subgroup analyses for our primary and
secondary outcomes according to the following variables: (a) baseline CHADS2 scores (0, 1, or ≥2); (b) patient age (<65 years, 65–74 years, 75–84 years,
≥85 years); (c) baseline anticoagulation use (yes versus
no); (d) patient sex.
Pretest comparisons between groups

We will compare groups on the numbers of patients
selected by GPs, patient sex, age (mean and median differences and on categorical groupings <65 years, 65–74,
75–84, ≥85 years), CHADS2 scores (0, 1, ≥2, and mean
scores), and use of oral anticoagulation (current at pretest, previous use, or never used).
Sample size estimate

Our study was powered to detect a 15% difference in
anticoagulation rates between groups. We assumed a
baseline use of anticoagulation of 50% to produce anticonservative (i.e., larger) estimates of the required sample
size. In the absence of a design effect, whereby the sample size would be adjusted for clustering of patients by
GP, we required GPs to identify 170 patients per group
or 340 in total [56]. As patient cases were clustered by
GP, we adjusted our sample size estimate by the design
effect Deff = 1 + (m − 1)ρ [57], where m equals the average

Ethics approval

The Human Research Ethics Committee of the University of New South Wales has approved the study
(UNSW HREC Reference Number 07067).

Discussion
Long-term anticoagulation for AF remains the treatment
of choice to prevent stroke in most people with AF. The
STOP STROKE in AF study has an active ‘control’. Information is delivered via academic detailing with tailored feedback about risk stratification and guideline
recommendations. The addition of expert decisional
support in our intervention arms allows for a direct test
of this component on GP self-reported patient management. The national geographical reach of the study and
feasible delivery of the intervention, via telephone and
mail, are innovations of the study.
Until recently, warfarin has been the only oral anticoagulant available for managing AF. Two fixed-dose
anticoagulants, dabigatran [46,47] and rivoroxaban [58],
have received approval for stroke prophylaxis in AF by
the US Federal Drug Administration (FDA). Apixaban
[59], another fixed-dose anticoagulant, is due to be
reviewed by the FDA in 2012. It is unclear whether the
advent of new drugs will improve anticoagulation rates.
In practice, uptake of dabigatran, the first FDA-approved
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fixed dose oral anticoagulant, has been described as ‘disappointing’, with an estimated 10% of AF patients using
the drug in the United States [60]. The cost of the drug,
the need for twice-daily dosing, a short shelf-life, the
lack of an antidote to reverse acute bleeding, the inability to determine the anticoagulation effects of dabigatran, and the increased risk of GI bleeding, dyspepsia,
discontinuation, and possibly myocardial infarction,
when compared with warfarin, may limit its broader uptake [58]. Recent warnings from regulators in Australia
[48] and the United States [61] have emphasised safety
concerns about dabigatran, particularly in those with
renal impairment and in elderly patients aged over
75 years. In Australia, AF became an approved indication for dabigatran by the local government regulator,
the TGA, after which the company manufacturing the
drug offered doctors free medication for a limited period
of time, or until the drug became subsidised by the Australian government (whichever occurred first). The Australian government has thus far declined the company’s
application to subsidise the drug. Federal agencies in
Australia are currently undertaking a further review of
the costs and benefits of the new drug and defining the
circumstances in which warfarin may be more cost effective. Other fixed-dose anticoagulants that may come
to market in the near future, specifically rivaroxaban and
apixaban, share some drawbacks of dabigatran; all three
lack an antidote to reverse acute bleeding, and apixaban
also requires twice-daily dosing.
Prescribing behaviour seems difficult to shift. The
South London secondary prevention programme, also
called Stop Stroke, enrolled 523 stroke survivors, 99 of
whom had AF. Patients were randomised to receive
‘keeping well plans’ summarising risk factors and management strategies, including evidence-based prescribing
for managing blood pressure, diabetes, and AF, that were
updated over a 12-month period [33]. The intervention
had no effect on any of the study outcomes, including
anticoagulant prescribing for AF patients.
Clinician fears about the side effects of anticoagulation
appear to have greater influence on anticoagulant prescribing than do concerns about stroke risk. Clinicians
are less likely to prescribe anticoagulation in patients
with AF if one of their AF patients receiving anticoagulation is hospitalised for a major bleed, yet prescribing
behaviour is not influenced if untreated AF patients are
hospitalised for an ischaemic stroke [62]. In our national
Australian survey [13,14], GPs with prior experiences of
a haemorrhagic stroke in AF patients report a heightened sense of responsibility for that outcome. In contrast, GPs with untreated AF patients who had a stroke
were no more likely to feel responsible for this outcome
than other GPs. Further, our survey showed that GPs
appeared overly cautious in prescribing anticoagulation
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in the presence of any perceived risk of bleeding, even
where treatment benefits clearly outweighed the risk of
harm. Other Australian surveys show that GPs are reluctant to prescribe anticoagulation for nonvalvular atrial
fibrillation in the elderly or in the presence of perceived
bleeding risks, which would not contraindicate anticoagulation according to available evidence [15-17].
The STOP STROKE in AF study aims to redress clinician wariness and concerns over the use of anticoagulation and support effective decision making to build
practitioner confidence and increase the appropriate uptake of anticoagulation in AF.
In addition to our own research, we are aware of one
other Australian study evaluating a risk assessment tool
in general practice for improving the management of AF
[63,64]. It is hoped that these studies will collectively
identify effective implementation strategies to better inform GPs on AF management, closing the evidence–
practice gap in Australia and elsewhere.
Progress

Required numbers of GPs have been recruited. We expect posttest data collection to be completed in 2012.
Results are expected in 2013.
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